Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. - Wikidata - wikimedia - TriplyDB

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

http://www.wikidata.org/entity/Q47573472

about

B-Raf and the inhibitors: from bench to bedside The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Melanoma: oncogenic drivers and the immune system ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma New developments in the management of advanced melanoma - role of pembrolizumab Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Universes collide: combining immunotherapy with targeted therapy for cancer Emerging targeted therapies for melanoma treatment (review)Pathways and therapeutic targets in melanoma Optimal management of metastatic melanoma: current strategies and future directions EZH2 as a mediator of treatment resistance in melanoma Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade Nivolumab in melanoma: latest evidence and clinical potential Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression Targeting the PD-1 pathway: a promising future for the treatment of melanoma.Understanding the biology of melanoma and therapeutic implications Oncogene withdrawal engages the immune system to induce sustained cancer regression.BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma Dabrafenib and its potential for the treatment of metastatic melanoma.Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma

P2860

Q21198860-6B68A026-973A-4729-9CAB-D587BC7CB932 Q26744335-5F2F19D2-F26A-42BF-BB06-C32D95A2C734 Q26751520-CA552D20-9EC0-4D58-9236-CB14C70099D0 Q26769870-C8FD5B1F-468C-42E6-83A6-B86572B11421 Q26771192-E3F1F3C0-9E0F-4A02-BA43-DAABCAABD31C Q26775598-2FFE86AC-7ABF-4BDC-9F75-7C446D5C66F7 Q26777288-665429FE-1D8F-4024-B0B9-E1C1F499DC58 Q26781931-D95D601A-CA08-4574-B1CF-9015192A1C72 Q26796309-4056893B-7B5B-4A6F-B685-7B44ACDE5ADD Q26799073-BF6278C5-682D-4320-A627-8FC1B174247B Q26799864-2F8D443C-8F3B-418A-AE9A-CEC9D280C784 Q26822793-1ACFA8CA-B355-4C7C-8E71-E7862970987C Q26824310-C6D3C0A8-14D2-4940-9882-AFC480E42628 Q26825316-6D85741F-762E-420B-87E3-DAF843201AB6 Q26829997-862D2DA1-4ECD-4C4E-896A-7DBD879FBF24 Q26865736-ADC77E84-E9DC-4EF1-9B1B-8E4DD695507C Q26997338-C01EFFDB-1722-49E4-848C-0CFD2DBEF23C Q28074492-E5E8337D-9400-41F8-95E2-C6D529B6D5DF Q28119095-879DD356-0B05-478E-AE5D-696AAE3D9E85 Q28258598-9935D779-EAEE-4E89-B0E0-356FFAF7C681 Q29994573-E9C7F5FD-1C2D-4704-9185-CF6E86B8E628 Q30274920-B7BF3539-D6CF-4BC7-BA0F-ED1D071FFF8D Q30408331-A5235CEC-F7C9-4D5E-BA9A-7CC643DB65C7 Q30411499-C7E3A56F-0A90-4FCB-97C4-8A40E8DF627E Q33762053-5AD016F4-14BB-44DC-A5BE-84DC01D32E57 Q33776925-C0BD0A0F-A7C7-41ED-8979-6346DCEE74CD Q33898182-9E8F5B41-9E90-4C8A-873B-276E28E79983 Q33931434-9BC9366F-0C9D-4A46-8ACF-A64146637F79 Q33946513-4B5F78D6-DAFF-4DC5-B206-67914EB28702 Q33978378-D789D87F-25D7-4786-99A7-898D518B187C Q33987633-E07D0572-4A6A-44D4-AE5D-5162F1744D5B Q33996674-7CF4D0FF-C1B2-4A11-B269-0E014D6BB54B Q34100838-B0B81FF5-F72F-4DE5-905E-A252F1B20AA3 Q34185078-5EC56E2D-FC58-4261-8C6D-335C514B724D Q34287452-67775701-6564-470C-8C6D-01B6A90BEA70 Q34361976-C83751C8-A557-4DF4-8FCA-4AEF6432BA0E Q34646279-82612411-1D4A-44C4-B24C-1F35E9982B58 Q34646614-53E561AC-975C-42F1-A275-B86787628EC3 Q34661815-3FFED5A0-3ED6-406E-91C1-18E819644772 Q34662717-C3B84D65-F599-4EB1-B7CF-237F645AE262

P2860

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

http://www.wikidata.org/entity/Q47573472

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@en

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@nl

type

label

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@en

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@nl

prefLabel

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@en

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@nl

P1433

Q47573472-E837328F-D577-42ED-8676-2B5D333C654A

P1476

Q47573472-105CA82B-7B1A-4864-A55C-842F71CDDDF9

P2093

Q47573472-3F6DCC36-8201-4051-BCF0-02A5ACC7B3BA

Q47573472-705F6D71-578B-42A0-9CAF-2F0912647A9B

Q47573472-93C95F01-D6BD-4D53-AA95-84A8B4D14EB9

Q47573472-AC92924F-BE4E-4854-AFE5-A20692744253

Q47573472-D57DF863-C5F6-4FFF-BE80-2772B4353A32

Q47573472-F0E630E1-3F64-4902-A529-3979E8A95269

P304

Q47573472-87F09890-1B84-4C6A-86DA-A8F01376C6A5

P31

Q47573472-60DF77DF-DBA1-4E6C-B156-1233F7FCE85D

P356

Q47573472-62150154-BD59-43A1-91A2-092708B6BF3F

P407

Q47573472-6227DAE9-1A06-4F6A-AF12-B1247FDD201B

P433

Q47573472-7CFE4D47-AD06-4AA3-8582-83B24BCB4919

P478

Q47573472-47C566B2-7618-4539-8771-5EFCAA142AC8

P50

Q47573472-73646308-3604-483B-9EB2-A12CAD407017

Q47573472-EED85C37-7E16-47E3-A6D8-DF0166AF0E18

Q47573472-EF7E5542-A260-4DB0-A169-78E64620DFA5

P577

Q47573472-C5C4588D-C4C4-4886-9DAA-52C8E9FB0A03

P698

Q47573472-980157DB-31D0-46DF-B3C4-AA464BC0C917

P356

1078-0432.CCR-11-2479

P1433

Clinical Cancer Research

P1476

Selective BRAF inhibitors indu ...... nto human metastatic melanoma.

@en

P2093

James S Wilmott

http://www.w3.org/2001/XMLSchema#string

John F Thompson

http://www.w3.org/2001/XMLSchema#string

Julie R Howle

http://www.w3.org/2001/XMLSchema#string

Lauren E Haydu

http://www.w3.org/2001/XMLSchema#string

Peter Hersey

http://www.w3.org/2001/XMLSchema#string

Raghwa N Sharma

http://www.w3.org/2001/XMLSchema#string

P304

1386-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-2479

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Richard A. Scolyer

Georgina V. Long

Richard F. Kefford

P577

2011-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22156613

http://www.w3.org/2001/XMLSchema#string